Treatment for myelodysplastic syndrome by hypomethylating agents may activate an oncogene

Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS), and increasingly in other diseases, but their mechanism of action is not clear. HMAs may affect many genes and could potentially activate an oncogene—a gene that contributes to the development of cancer—but this has not been clearly demonstrated to date.

source https://medicalxpress.com/news/2022-05-treatment-myelodysplastic-syndrome-hypomethylating-agents.html